Zydus Lifesciences' Q3 FY 2025-26 Quarterly Results
- 10 Feb 2026
Result Summary
- Zydus Lifesciences Ltd reported a 11.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 31.0%.
- Its expenses for the quarter were up by 22.8% QoQ and 33.7% YoY.
- The net profit decreased 17.4% QoQ and decreased 0.3% YoY.
- The earnings per share (EPS) of Zydus Lifesciences Ltd stood at 10.36 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 6975.90 | 6232.20 | 5326.60 | 11.9% | 31.0% |
Total Expenses | 5537.60 | 4510.60 | 4142.50 | 22.8% | 33.7% |
Profit Before Tax | 1353.40 | 1687.40 | 1184.10 | -19.8% | 14.3% |
Tax | 388.30 | 454.00 | 179.50 | -14.5% | 116.3% |
Profit After Tax | 1022.90 | 1238.60 | 1026.20 | -17.4% | -0.3% |
Earnings Per Share | 10.36 | 12.51 | 10.17 | -17.2% | 1.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Zydus Lifesciences Ltd is a leading pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of a diverse range of healthcare products. The company operates primarily in the pharmaceutical industry, focusing on formulations, active pharmaceutical ingredients (APIs), biosimilars, and complex generics. Zydus Lifesciences is known for its extensive portfolio that spans across therapeutic areas including cardiovascular, gastroenterology, women’s health, and respiratory diseases. As of the latest available data, there are no specific mentions of recent major developments for Zydus Lifesciences Ltd. However, the company's ongoing commitment to innovation and expansion into new markets is a cornerstone of its strategic initiatives.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Zydus Lifesciences Ltd reported a total income of ₹6975.90 crores. This represents a quarter-over-quarter (QoQ) increase of 11.9% from ₹6232.20 crores in Q2FY26 and a year-over-year (YoY) growth of 31.0% from ₹5326.60 crores in Q3FY25. The significant YoY increase highlights the company's growth trajectory in terms of revenue generation. These figures suggest that the company has been successful in enhancing its market presence and sales volumes during this period.
Profitability
The profitability metrics for Zydus Lifesciences Ltd in Q3FY26 show a mixed performance. The profit before tax (PBT) was reported at ₹1353.40 crores, marking a QoQ decline of 19.8% from ₹1687.40 crores in Q2FY26. However, on a YoY basis, there was a 14.3% increase from ₹1184.10 crores in Q3FY25. The tax expense in Q3FY26 was ₹388.30 crores, down 14.5% QoQ from ₹454.00 crores in Q2FY26, but it increased by 116.3% YoY from ₹179.50 crores in Q3FY25. The profit after tax (PAT) for Q3FY26 was ₹1022.90 crores, showing a QoQ decrease of 17.4% from ₹1238.60 crores in Q2FY26 and a slight YoY decrease of 0.3% from ₹1026.20 crores in Q3FY25.
Operating Metrics
The operating metrics reflect the efficiency and overall performance of Zydus Lifesciences Ltd during Q3FY26. Total expenses were reported at ₹5537.60 crores, representing a QoQ increase of 22.8% from ₹4510.60 crores in Q2FY26 and a YoY increase of 33.7% from ₹4142.50 crores in Q3FY25. This substantial rise in expenses indicates an increase in operational activities and possibly higher costs associated with production or expansion. The earnings per share (EPS) for Q3FY26 was ₹10.36, down 17.2% QoQ from ₹12.51 in Q2FY26 but up 1.9% YoY from ₹10.17 in Q3FY25. These figures provide insight into the company's financial health and shareholder value generation during the quarter.